Patent US4532135A successfully refreshed from Google Patents.
US4532135A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Renoprotective treatments employing vasodilator compounds
Assignee: Individual
•
Filing: 1982-09-27
•
Granted: 1985-07-30
•
Expires: 2002-09-27
Abstract
Abstract A treatment method and substances have been found to reduce the risk of incurring renal damage or failure. Vasodilators useful for the treatment of hypertension have been found to lower cholesterol levels and prevent renal failure or damage. These substances are administered alone or in combination with other substances useful in the treatment of hyperlipidemia such as phenoxyacetic acid derivatives. Suitable vasodilators include: hydralazine hydrochloride and functionally similar agents such as endralazine, trimazosin, minoxidil, and diazoxide; prazosin hydrochloride and functionally similar agents such as doxazosin, triodazosin, phentolamine hydrochloride, phenoxybenzamine hydrochloride, benextramine, indoramine, and yohimbine; clonidine HCl and functionally similar agents such as guanabenz, guanfacine, lofexidine, and UK No. 14,304; labetalol and other combined alpha and beta blocking agents such as prizidolol and peroxidil.
Inventors
- 👤 K. David G. Edwards
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 06:00
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/21; A61K31/215; A61K31/22
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
74 words
A method of treating renal damage or failure in a host in need of treatment comprising administering to said host an effective amount for treating renal failure or damage, a vasodilator having postsynaptic alpha-adrenoceptor blocking activity and having antihyperlipidemic characteristics which lower the lipid levels in the bloodstream of the host, said vasodilator being selected from a group consisting of endralazine, trimazosin, minoxidil, diazoxide, doxazosin, triodazosin, phentolamine hydrochloride, phenoxybenzamine hydrochloride, benextramine, indoramine, and yohimbine.
Claim 2
Independent Claim
74 words
A method of treating renal damage or failure in a host in need of treatment comprising administering to said host an effective amount for treating renal failure or damage, a vasodilator having postsynaptic alpha-adrenoceptor blocking activity and having antihyperlipidemic characteristics which lower the lipid levels in the bloodstream of the host, said vasodilator being selected from a group consisting of endralazine, trimazosin, minoxidil, diazoxide, doxazosin, triodazosin, phentolamine hydrochloride, phenoxybenzamine hydrochloride, benextramine, indoramine, and yohimbine.
Claim 3
Dependent Claim
38 words
A method of treating renal damage or failure in accordance with claim 1 wherein the vasodilator is trimazosin and the trimazosin is administered to the host in substantially daily quantities totalling approximately from 100 milligrams to 900 milligrams.
Claim 4
Dependent Claim
38 words
A method of treating renal damage or failure in accordance with claim 1 wherein the vasodilator is minoxidil, and the minoxidil is administered to the host in substantially daily quantities totalling approximately from one milligram through 30 milligrams.
Claim 5
Dependent Claim
35 words
A method of treating renal damage or failure in accordance with claim 1 wherein the vasodilator is diazoxide, intravenously administered to the host in substantially daily quantities totalling approximately from 250 milligrams through 500 milligrams.
Claim 6
Dependent Claim
40 words
A method of treating renal damage or failure in accordance with claim 1 wherein the vasodilator is phentolamine hydrochloride, and the phentolamine hydrochloride is administered to the host in substantially daily quantities totalling approximately from 200 milligrams through 900 milligrams.
Claim 7
Dependent Claim
40 words
A method of treating renal damage or failure in accordance with claim 1 wherein the vasodilator is phenoxybenzamine hydrochloride, and the phenoxybenzamine hydrochloride is administered to the host in substantially daily quantities totalling approximately from 5 milligrams through 50 milligrams.
Claim 8
Dependent Claim
38 words
A method of treating renal damage or failure in accordance with claim 1 wherein the vasodilator is benextramine, and the benextramine is administered to the host in substantially daily quantities totalling from approximately 10 milligrams through 100 milligrams.
Claim 9
Dependent Claim
38 words
A method of treating renal damage or failure in accordance with claim 1 wherein the vasodilator is indoramine, and the indoramine is administered to the host in substantially daily quantities totalling approximately from 40 milligrams through 120 milligrams.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-07-29 | 1989-01-28 | 1989-07-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-07-29 | 1993-01-28 | 1993-07-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-07-29 | 1997-01-28 | 1997-07-30 | $7700.00 | Window Closed / Lapsed |